Cargando…

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parigi, Tommaso Lorenzo, Torres, Maria Corina Plaz, Aghemo, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933124/ https://www.ncbi.nlm.nih.gov/pubmed/31042864 http://dx.doi.org/10.3350/cmh.2019.0022

Ejemplares similares

Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
por: Solitano, Virginia, et al.
Publicado: (2021)

What do clinicians need to watch for with direct‐acting antiviral therapy?
por: Aghemo, Alessio, et al.
Publicado: (2018)

Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life
por: Pugliese, Nicola, et al.
Publicado: (2023)

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
por: Fierer, Daniel S, et al.
Publicado: (2020)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
por: Nabulsi, Nadia A., et al.
Publicado: (2020)

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
por: Rossi, Carmine, et al.
Publicado: (2019)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

2197. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
por: Pritchard, Haley, et al.
Publicado: (2018)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Metallo-antiviral aspirants: Answer to the upcoming virusoutbreak
por: Mehrotra, Ripul, et al.
Publicado: (2023)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods
por: Loggi, Elisabetta, et al.
Publicado: (2017)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
por: Plaz Torres, Maria Corina, et al.
Publicado: (2019)

2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
por: Hosry, Jeff, et al.
Publicado: (2018)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tvk4pdm3d2tsb2r9nris28r3f6